Oncology · Breast CancerTrial Updateclinicalmid-term

Study on Animated Video and Booklet to Enhance Breast Cancer Awareness in Palestinian Women

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/1/2026, 6:30:12 AM

Assessment confidence: 79% · The main uncertainty is whether clinical benefit translates into regulatory momentum and guideline influence.

Executive Thesis

This study addresses a critical gap in breast cancer awareness and screening among Palestinian women, potentially leading to improved health outcomes in underserved populations. The results could inform future educational interventions and public health strategies in similar contexts, making it relevant for pharma companies involved in oncology and women's health. Regulatory context from FDA (Ongoing | Cancer Accelerated Approvals) supports the near-term read. Assessment grounded in 16 ranked evidence items (13 high-relevance).

Strategic Assessment

Success in this trial could lead to scalable educational strategies that improve screening rates and early detection of breast cancer in underserved populations. The strongest clinical anchor is The Effect of Animation Video and Training Booklet Designed on Breast Cancer (ClinicalTrials.gov), sub-indication match (breast cancer). In breast cancer, 3 regulatory and 3 competitive items passed relevance filtering for breast cancer screening programs.

Competitive Pressure

The most relevant competitive pressure comes from FDA Accepts NDA for Roche's Giredestrant in Early-Stage ER-Positive Breast Cancer (Humanexa Signals) — sub-indication match (breast cancer); sponsor/company relevance (roche). Secondary pressure from FDA Accepts NDA for Roche's Giredestrant in Early-Stage ER-Positive Breast Cancer.

Regulatory Outlook

Regulatory risk is concentrated around Ongoing | Cancer Accelerated Approvals (FDA). Regulatory pathway relevance (approval). The trial's outcomes are unlikely to directly affect regulatory approvals or compliance but may influence future guidelines on educational interventions in cancer care.

Key Opportunities

If successful, the study could enhance the market for educational tools and interventions related to breast cancer, potentially increasing demand for related pharmaceutical products and services in the region.
Oncology · Breast Cancer · Regulatory Approval · Giredestrant is positioned to potentially become the new standard-of-care in adjuvant treatment for early-stage ER-positive breast cancer, a significant advancement in over 20 years.
Oncology · Breast Cancer · Regulatory Approval · Giredestrant is positioned to potentially become the new standard-of-care in early-stage ER-positive breast cancer, impacting existing therapies.
Upside for breast cancer screening programs may improve if The tumor microenvironment in triple negative breast cancer and a strategy to improve responses to immunotherapy using cryoablation and immunostimulants. (PubMed) delivers favorable follow-through.
This listing includes accelerated approvals (AAs) for malignant hematology and oncology indications that have postmarketing requirement(s) for ongoing clinical trial(s) to verify clinical benefit.

What Would Change This Assessment

This becomes more urgent if Monitor the trial's progress, participant recruitment, and preliminary results expected after the intervention phase in late 2026.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

Ongoing | Cancer Accelerated Approvals
FDAmedium relevance
Regulatory pathway relevance (approval)
FDA document
View source
Withdrawn | Cancer Accelerated Approvals
FDAmedium relevance
Regulatory pathway relevance (approval)
FDA document
View source
Oncology (Cancer)/Hematologic Malignancies Approval Notifications
FDAmedium relevance
Regulatory pathway relevance (approval)
FDA document
View source
FDA Approves New Treatment That Uses Donor Immune Cells to Prevent Serious Complications in Blood Cancer Patients
FDAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Janus Kinase (JAK) inhibitors: Drug Safety Communication - FDA Requires Warnings about Increased Risk of Serious Heart-related Events, Cancer, Blood Clots, and Death
FDAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

The Effect of Animation Video and Training Booklet Designed on Breast Cancer
ClinicalTrials.govhigh relevance
Sub-indication match (breast cancer)
FDA document
View source
Imaging Study of TROP2 Binder in Metastatic UC, HR+ and HER2- Breast Cancer, TNBC, and NSCLC
ClinicalTrials.govhigh relevance
Sub-indication match (breast cancer)
FDA document
View source
Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer
ClinicalTrials.govhigh relevance
Sub-indication match (breast cancer)
FDA document
View source
Multi-epitope Folate Receptor Alpha Peptide Vaccine, GM-CSF, and Cyclophosphamide in Treating Patients With Triple Negative Breast Cancer
ClinicalTrials.govhigh relevance
Sub-indication match (breast cancer)
FDA document
View source
Phase Ib Study of Avutometinib, Defactinib, and Everolimus in RAS Pathway Mutant Endometrial Cancer
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial)
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Cuidar-ME, Web-based Psychological Intervention for (Peri)Menopausal Women: A Pilot Randomized Controlled Trial
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Clinical Study to Evaluate SIIPL qHPV Vaccine (CERVAVAC®) in Women Living With HIV Aged 15-25 Years
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

FDA Accepts NDA for Roche's Giredestrant in Early-Stage ER-Positive Breast Cancer
Humanexa Signalshigh relevance
Sub-indication match (breast cancer); Sponsor/company relevance (Roche)
FDA Accepts NDA for Roche's Giredestrant in Early-Stage ER-Positive Breast Cancer
Humanexa Signalshigh relevance
Sub-indication match (breast cancer); Sponsor/company relevance (Roche)
FDA Approval Update for IBRANCE (Palbociclib) by Pfizer
Humanexa Signalshigh relevance
Sub-indication match (breast cancer); Sponsor/company relevance (Pfizer)

Knowledge mapping and research trends of chimeric antigen receptor T-cell immunotherapy in breast cancer: A bibliometric and visual analytics study.
PubMedhigh relevance
Sub-indication match (breast cancer)
FDA document
View source
Automated Diagnosis of Breast Cancer Using Deep Learning Techniques Applied to Digital Mammography and Magnetic Resonance Images.
PubMedhigh relevance
Sub-indication match (breast cancer)
FDA document
View source
NSUN2 mediates SALL2 m5C methylation to inhibit ferroptosis and promote breast cancer progression.
PubMedhigh relevance
Sub-indication match (breast cancer)
FDA document
View source
Breast cancer screening in Europe and the role of general practitioners: A 32-country comparative survey.
PubMedhigh relevance
Sub-indication match (breast cancer)
FDA document
View source
The tumor microenvironment in triple negative breast cancer and a strategy to improve responses to immunotherapy using cryoablation and immunostimulants.
PubMedhigh relevance
Sub-indication match (breast cancer)
FDA document
View source
Suppression of LncRNA AC008406.3 sensitizes breast cancer cells to docetaxel via triggering cuproptosis.
PubMedhigh relevance
Sub-indication match (breast cancer)
FDA document
View source
Elevated ESR2 and BRCA1 gene expression in adenomyosis associated with endometrial cancer: a pilot study.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
RBM15B-mediated m6A modification of FOXM1 activates the AURKA/TPX2 axis to promote epithelial-mesenchymal transition-driven endometrial cancer progression.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

breast cancer screening programs

Commercial impact

medium

If successful, the study could enhance the market for educational tools and interventions related to breast cancer, potentially increasing demand for related pharmaceutical products and services in the region.

Regulatory impact

low

The trial's outcomes are unlikely to directly affect regulatory approvals or compliance but may influence future guidelines on educational interventions in cancer care.

What to watch

Monitor the trial's progress, participant recruitment, and preliminary results expected after the intervention phase in late 2026.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.